Last reviewed · How we verify
Chlorhexidine 0.12% mouthrinse
At a glance
| Generic name | Chlorhexidine 0.12% mouthrinse |
|---|---|
| Also known as | FluxProChlorhexidine 0.12% |
| Sponsor | University of Oslo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse. (NA)
- A Clinical Study of Connective Tissue Graft and Enamel Matrix Derivative in the Treatment of Intrabony Periodontal Defects (NA)
- Comparative Effects of Two Oral Antiseptics Used as an Adjuvant in the Treatment of Periodontitis (NA)
- Effects of Mechanical, Chemical, and Combination Methods on Halitosis (NA)
- Systemic Amoxicillin Plus Metronidazole in Peri-implantitis Treatment (PHASE4)
- Comparing Mouth Rinses (and Chewing Gum) in Regard to Streptococcus Mutans Reduction (PHASE2)
- Chlorhexidine Mouthrinse Before EBUS-TBNA (PHASE4)
- Role of Infected Blood Dendritic Cells in Heart Disease Risk (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlorhexidine 0.12% mouthrinse CI brief — competitive landscape report
- Chlorhexidine 0.12% mouthrinse updates RSS · CI watch RSS
- University of Oslo portfolio CI